Novo Nordisk (NVO) Q2 2025 Earnings Call August 07, 2025 08:15 AM ET Company ParticipantsJames Quigley - Executive DirectorKarsten Knudsen - EVP, CFO & Member of the Management BoardLudovic Helfgott - EVP - Product & Portfolio StrategyDavid Moore - EVP - US OperationsMartin Lange - Executive VP - R&D and Chief Scientific OfficerJacob Martin Wiborg Rode - Head - IRThibault Boutherin - Executive Director - Equity ResearchSimon Baker - Partner & Head - Global Biopharma ResearchHarry Sephton - Director - Pharma ...

Core Viewpoint - Hims & Hers Health, Inc. is facing allegations of deceptive practices related to the promotion and sale of illegitimate versions of Wegovy®, which may jeopardize its collaboration with Novo Nordisk and mislead investors about the company's prospects [2]. Group 1: Allegations and Legal Action - The class period for the allegations against Hims & Hers Health, Inc. is from April 29, 2025, to June 23, 2025 [2]. - Allegations include that Hims engaged in deceptive promotion and selling of illegitimate versions of Wegovy®, risking patient safety [2]. - The complaint suggests that the misleading statements from the company created a false impression of its business operations and future prospects [2]. Group 2: Shareholder Information - Shareholders who purchased shares during the class period are encouraged to register for potential lead plaintiff appointment, with a deadline of August 25, 2025 [3]. - Once registered, shareholders will receive updates through a portfolio monitoring software regarding the case's progress [3]. - Participation in the case incurs no cost or obligation for shareholders [3]. Group 3: Law Firm Background - The Gross Law Firm is a nationally recognized class action law firm focused on protecting investors' rights against deceit and fraud [4]. - The firm aims to ensure companies adhere to responsible business practices and seeks recovery for investors affected by misleading statements [4].

https://securitiesclasslaw.com/securities/novo-nordisk-a-s-loss-submission-form-3/?id=159960&from=4 NEW YORK, Aug. 7, 2025 /PRNewswire/ -- The Gross Law Firm issues the following notice to shareholders of Novo Nordisk A/S (NYSE: NVO). NEXT STEPS FOR SHAREHOLDERS: Once you register as a shareholder who purchased shares of NVO during the timeframe listed above, you will be enrolled in a portfolio monitoring software to provide you with status updates throughout the lifecycle of the case. The deadline to seek ...

Core Insights - Novo Nordisk A/S (NVO) reported strong quarterly earnings driven by its weight-loss drug and diabetes franchise, indicating ongoing growth potential [1] - Despite the positive earnings report, NVO's shares experienced a decline, continuing a trend of significant price drops in recent weeks [1] Company Performance - The earnings results highlighted the effectiveness of NVO's weight-loss drug and diabetes products, contributing to appealing growth metrics [1] - The company's focus on cash generation and durable business models aligns with investment strategies that prioritize long-term value [1] Market Reaction - NVO's share price fell following the earnings announcement, suggesting market skepticism despite the reported growth [1]

Company Overview - Novo Nordisk is a pharmaceutical giant based in Denmark, focusing on Diabetes Care, Obesity Care, and Rare Diseases [1] - The company is well-known for its flagship products, Ozempic and Wegovy, which are used to treat diabetes and obesity [1] Analyst Background - The analyst has a decade of experience at a Big 4 audit firm, specializing in banking, mining, and energy sectors [1] - Currently serves as the Head of Finance for a leading retail real estate owner and operator, overseeing complex financial operations and strategy [1] - The analyst has been an active investor in the U.S. stock market for 13 years, with a portfolio that reflects a balanced approach focusing on value stocks and growth opportunities [1] Investment Philosophy - The investment philosophy is rooted in thorough research and a long-term perspective, which has been beneficial in navigating various market cycles [1] - The aim is to uncover promising under-the-radar stocks that may not yet be recognized by the broader market [1] - The combination of auditing and finance background with hands-on investing experience allows for unique insights and actionable ideas for investors [1]

Core Viewpoint - Hims & Hers Health experienced a significant decline in stock price due to lower revenue expectations from its personalized GLP-1 weight loss medication, leading to a nearly 11% drop in shares on August 5, 2025 [1][3]. Financial Performance - The company's total revenue for Q2 2025 was $545 million, reflecting a 7% sequential decline [3]. - Revenue from compounded GLP-1 weight-loss drugs decreased to $190 million from $230 million in the previous quarter [3]. - Revenue per subscriber fell to $74 from $84, attributed to the off-boarding of some GLP-1 subscribers [3]. Legal Issues - Hims & Hers is facing a securities class action lawsuit related to a terminated collaboration with Novo Nordisk, which was intended to expand access to the FDA-approved weight loss drug Wegovy® [2][5]. - The lawsuit alleges that the company engaged in deceptive promotion and selling of illegitimate versions of Wegovy®, which jeopardized patient safety and led to the termination of the partnership with Novo Nordisk [6]. - Following the announcement of the partnership termination on June 23, 2025, Hims' stock price plummeted over 34% [6]. Business Model Shift - The company has shifted its business model after the FDA ended mass compounding of certain weight-loss drugs, now focusing on personalized, smaller-dose compounded versions [4]. - Hims & Hers previously touted its collaboration with Novo Nordisk but lost it due to regulatory concerns regarding its practices [4].

From @WSJopinion: Eli Lilly and Novo Nordisk are trying to transform how patients access medication, and Washington has done its part. It’s time to let consumers roar into a competitive marketplace—without government intervention, writes Stephen Buck. https://t.co/OKYWoEYHl1 ...

The class action concerns whether Novo Nordisk and certain of its officers and/or directors have engaged in securities fraud or other unlawful business practices. NEW YORK, Aug. 6, 2025 /PRNewswire/ -- Pomerantz LLP announces that a class action lawsuit has been filed against Novo Nordisk A/S ("Novo Nordisk" or the "Company") (NYSE: NVO). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, (or 888.4-POMLAW), toll-free, Ext. 7980. Those who inquire by e-mail are encour ...

Financial Data and Key Metrics Changes - In the first six months of 2025, the company achieved 18% sales growth and 29% operating profit growth [8][42] - The gross margin decreased to 83.4% compared to 84.9% in 2024, primarily due to amortizations and depreciations related to Catalent [42] - Net profit increased by 22% and diluted earnings per share rose by 23% to DKK 12.49 [46] Business Line Data and Key Metrics Changes - U.S. Operations sales grew by 17%, while international operations grew by 19% [12] - GLP-1 diabetes care sales in the U.S. increased by 9%, driven by Ozempic, while obesity care sales surged by 58% [12][19] - Rare disease sales increased by 15%, with U.S. operations growing by 23% [15] Market Data and Key Metrics Changes - The company serves nearly 46 million patients with diabetes and obesity treatments, an increase of over 3.5 million patients compared to the first half of 2024 [10] - In international operations, GLP-1 diabetes sales increased by 10%, while obesity care sales grew by 125% [22] - The company holds a 71% market share in the GLP-1 segment in international operations [24] Company Strategy and Development Direction - The company aims to expand its diabetes and obesity markets, targeting new patient groups and physician segments [30] - A focus on innovation and operational efficiency is emphasized, with plans to enhance commercial execution [59] - The company is investing in a broad portfolio of treatments to address diverse patient segments in the obesity market [30] Management's Comments on Operating Environment and Future Outlook - Management has lowered the full-year outlook for 2025 due to lower growth expectations for Wegovy and Ozempic in the U.S. [9][49] - The company remains confident in its ability to treat more patients with chronic diseases despite the adjustments in expectations [54] - The management highlighted the importance of addressing the unmet needs in diabetes and obesity globally [28] Other Important Information - The company has initiated a Phase III clinical development program for amicretin, targeting obesity and associated comorbidities [35] - The company plans to launch oral semaglutide for obesity in the U.S. next year without supply restrictions [103] - An interim dividend of DKK 3.75 per share has been announced, reflecting a 7% increase compared to the previous year [48] Q&A Session Summary Question: What is the impact of Wegovy's formulary position with CVS? - Management is pleased with the conversion from the CVS formulary and is seeing results in line with expectations [66] Question: Has Novo initiated any litigation regarding compounding practices? - The company is prioritizing patient safety and is in dialogue with the FDA regarding illegal compounding practices, but specifics on litigation were not disclosed [68] Question: What is the outlook for growth in China? - Management clarified that the lower growth in China is due to destocking rather than loss of market share, and they are confident in future growth potential [75] Question: What changes in R&D focus can be expected? - The company will focus more on diabetes and obesity, reallocating resources to enhance growth in these core areas [82] Question: How is the company positioned for the launch of oral semaglutide? - The company is well-positioned for the launch of oral semaglutide for obesity next year, with no supply restrictions anticipated [103] Question: What are the pricing strategies for Wegovy and Ozempic? - Management is focused on volume growth but is also considering pricing strategies for the second half of the year [116]

Financial Data and Key Metrics Changes - In the first six months of 2025, the company achieved 18% sales growth and 29% operating profit growth [7][44] - The gross margin decreased to 83.4% compared to 84.9% in 2024, primarily due to amortizations and depreciations related to Catalent [44] - Net profit increased by 22% and diluted earnings per share rose by 23% to DKK 12.49 [48] Business Line Data and Key Metrics Changes - U.S. Operations grew by 17%, while international operations grew by 19% in total sales [12] - GLP-1 diabetes sales in the U.S. increased by 9%, driven by Ozempic, while obesity care sales surged by 58% [12][19] - Rare disease sales increased by 15%, with U.S. operations growing by 23% [15] Market Data and Key Metrics Changes - Sales in international operations grew by 19%, with GLP-1 diabetes sales increasing by 10% [23] - Obesity care sales in international operations grew by 125%, with Wegovy sales alone reaching DKK 12.2 billion, growing at 335% [24] - The company remains the market leader in international operations with a 71% market share in GLP-1 products [25] Company Strategy and Development Direction - The company aims to expand its diabetes and obesity markets, targeting new patient groups and physician segments [31] - A focus on innovation and addressing diverse patient segments through a broad portfolio of treatments is emphasized [31] - The company plans to continue rolling out Wegovy in more countries and invest in commercial execution [26][31] Management's Comments on Operating Environment and Future Outlook - Management has lowered the full-year outlook for 2025 due to lower growth expectations for Wegovy and Ozempic in the U.S. [7][51] - The company is confident in its ability to treat more people living with chronic diseases despite the adjustments in expectations [56] - The management highlighted the importance of operational efficiency and commercial execution moving forward [60] Other Important Information - The company announced an interim dividend of DKK 3.75 per share, a 7% increase compared to August 2024 [49] - Capital expenditure for 2025 is expected to be around DKK 65 billion, reflecting expansion of the global supply chain [54] Q&A Session Summary Question: What is the impact of Wegovy's formulary position with CVS? - Management is pleased with the CVS formulary conversion and sees it aligning with expectations, but specific numbers on lives affected were not disclosed [67][68] Question: Has Novo initiated any litigation regarding compounding practices? - Management confirmed that protecting patient safety is a priority and that legal actions are being considered, with ongoing dialogue with the FDA [68][69] Question: What is the outlook for growth in China? - Management stated that the lower growth in China is due to destocking rather than loss of market share, and they are confident in future growth due to unmet needs [75][78] Question: What changes in R&D focus can be expected? - Management indicated a continued focus on diabetes and obesity, emphasizing execution and reallocating resources to areas of growth [81][83] Question: What is the rationale behind discontinuing development of Sulfiram for NASH? - The decision was based on a lack of differentiation from semaglutide in trials, which demonstrated strong efficacy [112][113]